The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of TP53 mutations in actionable driver-negative non-small cell lung cancer (NSCLC).
 
Jie Chi
No Relationships to Disclose
 
Nishant Gandhi
Employment - Caris Life Sciences
 
Balasz Halmos
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Sanofi; Takeda
Research Funding - Abbvie (Inst); Alkermes (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
 
Patrick C. Ma
Honoraria - AstraZeneca; BeiGene
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Elevation Oncology (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); OncoC4 (Inst); Roche/Genentech (Inst)
 
Andrew Elliott
Employment - Caris Life Sciences
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - George Clincal; West Clinic
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca (I); Daiichi Sankyo/Astra Zeneca; Genentech; MorphoSys (I); Seagen (I); Zentalis
Speakers' Bureau - BeiGene (I)
Research Funding - AstraZeneca (Inst)